An in vitro investigation of the anti-inflammatory properties of potassium humate

Inflammation

Volumn 28, Issue 3, 2004, Pages 169-174

  Jooné, Gisela Käthe ^a   Van Rensburg, Constance Elizabeth Jansen ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

anti inflammatory; CR3; degranulation; potassium humate

Indexed keywords

ANTIINFLAMMATORY AGENT; COAL; FORMYLMETHIONYLLEUCYLPHENYLALANINE; HUMATE POTASSIUM; INTERCELLULAR ADHESION MOLECULE 1; PHORBOL 13 ACETATE 12 MYRISTATE; POLYPEPTIDE; POTASSIUM DERIVATIVE; SEPHADEX; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL LINE; CELL MEMBRANE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGRANULATION; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; PHAGOCYTE; PROTEIN EXPRESSION; TISSUE INJURY;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL DEGRANULATION; CELLS, CULTURED; COAL; CRICETINAE; EOSINOPHILS; HUMANS; HUMIC SUBSTANCES; MACROPHAGE-1 ANTIGEN; NEUTROPHILS; POTASSIUM;

ANIMALIA; CRICETINAE;

EID: 4444219507     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:IFLA.0000039563.90066.5d     Document Type: Article

References (36)

1. Hartenstein, R. 1981. Sludge decomposition and stabilization. Science 212:743-749.
2. Visser, S. A. 1973. Some biological effects of humic acids in the rat. Acta. Biol. Med. Germ. 31:569-581.
3. Baatz, H. 1988. Moortherapie en der Frauenheilkunde. In: Moortherapie: Grundlagen und Anwendungen, W. Flaig, C. Goecke, and W. Kauffels, eds. Ueberreuter, Wien-Berlin, pp. 161-168.
4. Kleinschmidt, J. 1988. Moortherapie bei rheumatischen Erkrankungen. In: Moortherapie: Grundlagen und Anwendungen, W. Flaig, C. Goecke, and W. Kauffels, eds. Ueberreuter, Wien-Berlin, pp. 216-224.
5. Kovarik, R. 1988. Über die Anwendung von Präparaten aus Torf, bzw. Huminstoffen bei gynäkologischen Erkrankungen. In: Moortherapie: Grundlagen und Anwendungen, W. Flaig, C. Goecke, and W. Kauffels, eds. Ueberreuter, Wien-Berlin, pp. 177-197.
6. Lent, W. 1988. Bericht über die Moorforschung und anwendung in der DDR, Polen, Tschechoslowakei und UdSSR. In: Moortherapie: Grundlagen und Anwendungen, W. Flaig, C. Goecke, and W. Kauffels eds. Ueberreuter, Wien-Berlin, pp. 169-176.
7. Goel, R. K., R. S. Banerjee, and S. B. Acharya. 1990. Antiulcerogenic and antiinflammatory studies with Shilajit. J. Ethnopharmacol. 29:95-103.
8. Schepetkin, I., A. Khlebnikov, and B. S. Kwon. 2002. Medical drugs from humus matter: Focus on Mumie. Drug Dev. Res. 57:140-159.
9. Soliev, T. S. 1983. The treatment of deforming osteoarthrosis by non-specific bio-stimulator Mumie. Med. J. Uzbek 8:19-21.
10. Cloete, T. E., H. Swart, I. J. Cronje, and J. Dekker. 1990. Oxidized coal products as industrial bactericides. In: Third International Symposium on Gas, Oil, Coal and Environmental Biotechnology, New Orleans, Louisiana, December 3-5.
11. van Rensburg, C. E. J., A. van Straten, and J. Dekker. 2000. An in vitro investigation of the antimicrobial activity of oxifulvic acid. J. Antimicrob. Chemother. 46:853-854.
12. van Rensburg, C. E. J., S. C. K. Malfeld, and J. Dekker. 2002. Topical application of oxifulvic acid suppresses the cutaneous immune response in mice. Chemotherapy 48:138-143.
13. Snyman, J. R., J. Dekker, S. C. K. Malfeld, and C. E. J. van Rensburg. 2002. A pilot study to evaluate the safety and therapeutic efficacy of topical oxifulvic acid in atopic volunteers. Drug Dev. Res. 57:40-43.
14. Jooné, G. K., J. Dekker, and C. E. J. van Rensburg. 2003. Investigation of the immunostimulatory properties of oxihumate. Z. Naturforsch. Redaktion. 58:263-267.
15. Bansal, V. S., S. Vaidya, E. P. Somers, M. Kanuga, D. Shevell, R. Weikel, and P. A. Detmers. 2003. Small molecule antagonists of complement receptor type 3 block adhesion and adhesion-independent oxidative burst in human polymorphonuclear leukocytes. J. Pharmacol. Exp. Ther. 1016-1024.
16. Håkanson, L., M. D. Björnsson, C. Janson, and M. D. Schmekel. 1995. Increased adhesion to vascular cell adhesion molecule-1 of eosinophls from patients with asthma. J. Allergy Clin. Immunol. 96:941-950.
17. Ballesteros, J. F., M. J. Sanz, A. Ubeda, M. A. Miranda, S. Iborra, M. Paya, and M. J. Alcaraz. 1995. Synthesis and pharmacological evaluation of 2′-hydroxychalcones and flavones as inhibitors of inflammatory mediators generation. J. Med. Chem. 38:2794-2797.
18. Blackburn, W. D., Jr., L. W. Heck, L. D. Loose, J. D. Eskra, and T. J. Carty. 1991. Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis. Arthritis Rheum. 34:204-210.
19. Spisani, S. S. Traniello, A. M. Onori, C. Martuccio, and L. Cellai. 1998. 3-(Carboxalkylthio) rifamycin S and SV derivatives inhibit human neutrophil functions. Inflammation 22:459-469.
20. Bergh, J. J., I. J. Cronje, J. Dekker, T. G. Dekker, L. M. Gerritsma, and L. J. Mienie. 1997. Non-catalytic oxidation of water-slurried coal with oxygen: Identification of fulvic acids and acute toxicity. Fuel 76:149-154.
21. Piccolo, A., P. Conte, and A. Cozzolino. 2000. Differences in high performance size exclusion chromatography between humic substances and macromolecular polymers. In: Humic Substances: Versatile Components of Plants, Soils and Water, E. A. Ghabbour and G. Davies, eds. Royal Society of Chemistry, Cambridge, UK, pp. 111-124.
22. Håkanson, L., L. S. Nielson, and P. Teder. 1994. Measurement of neutrophil and eosinophil adhesion to E-selectin, VCAM-1 and ICAM-1 by the use of transfected fibroblast cell lines. J. Immunol. Methods 176:53-66.
23. Böyum, A. 1968. Isolation of leucocytes from human blood. Further observations: Methylcellulose, dextran, and ficoll as erythrocyte aggregating agents. Scand. J. Clin. Lab. Invest. 21:31-50.
24. Ras, G. J., R. Anderson, G. W. Taylor, J. E. Savage, E. van Niekerk, G. Joone, H. J. Koornhof, J. Saunders, R. Wilson, and P. J. Cole. 1992. Clindamycin, erythromycin, and roxithromycin inhibit the proinflammatory interactions of Pseudomonas aeruginosa pigments with human neutrophils in vitro. Antimicrob. Agents Chemother. 36(6):1236-1240.
25. Weiss, S. J. 1989. Tissue destruction by neutrophils. N. Engl. J. Med. 320:365-376.
26. Jaeschke, H., A. Farhood, A. P. Bautista, Z. Spolarics, J. J. Spitzer, and C. W. Smith. 1993. Functional inactivation of neutrophils with Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. Hepatology 17:915-923.
27. Jaeschke, H., A. Farhood, and C. W. Smith. 1991. Neutrophil induced liver cell injury in endotoxin shock is a CD11b/CD18-dependant mechanism. Am. J. Physiol. 261:G1051-G1056.
28. Burch, R. M., M. Weitzberg, L. Noronha-Blob, V. C. Lowe, J. M. Bator, J. Perumattam, and J. P. Sullivan. 1992. Leumedins. Drug News Prospect. 5:331-337.
29. Stadnyk, A. W., D. Dollard, T. B. Issekutz, and A. C. Issekutz. 2002. Neutrophil migration into indomethacin induced rat small intestinal injury is CD11a/CD18 and CD11b/CD18 co-dependant. Gut 50:629-635.
30. Ramamoorthy C., S. S. Sasaki, D. L. Su, S. R. Sharar, J. M. Harlan, and R. K. Winn. 1997. CD18 adhesion blockade decreases bacterial clearance and neurophil recruitment after intrapulmonary E. coli but not S. aureus. J. Leukoc. Biol. 61:167-172.
31. Klebanoff, S. J. and R. A. Clark. 1978. The Neutrophil: Functions and Clinical Disorders. Elsevier Scientific, Amsterdam.
32. Venge P. 1990. The human eosinophil in inflammation. Agents Actions 29:122-126.
33. Nègre, M., H. R. Schulten, M. Gennari, and D. Vindrola. 2001. Interaction of imidazolinone herbicides with soil humic acids. Experimental results and molecular modeling. J. Environ. Sci. Health, Part B 36:107-125.
34. Sato, T., Y. Ose, H. Nagase, and K. Hayase. 1987. Adsorption of mutagens by humic acid. Sci. Total Environ. 62:305-310.
35. Cozzi, R., M. Nicolai, P. Perticone, R. De Salvia, and F. Spuntarelli. 1993. Desmutagenic activity of natural humic acids: Inhibition of mitomycin C and maleic hydrazide mutagenicity. Mutat. Res. 299:37-44.
36. Botes, M. E., J. Dekker, and C. E. J. van Rensburg. 2002. Phase I trial with oral oxihumate in HIV-infected patients. Drug Dev. Res. 57:34-39.